mktcap_usd=139632
ConsensRecom=2.26
earning_yield=3.20%
growth=14.41%
dilution=4.07%
div_ratio=90.82%
sh_payout_ratio=0
margin=10.05%
cfmargin=13.46%
ratiopaid=24.13%
sratiopaid=0
ratioConsens=1.22
Description
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and hematology. Its pharmaceutical products include chemically synthesized or small molecule drugs and products produced from biological processes, called biologics. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Abecma, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Camzyos, and Breyanzi. It also has a pipeline of investigational medicines designed to target the common mutations associated with oncogenesis, including repotrectinib. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.
Income and Cashflow Statements USD
| EndDate | 2016-12-31 | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | mean | std |
|---|---|---|---|---|---|---|---|---|---|
| sourceDate | 2017-02-21 | 2018-02-13 | 2019-02-25 | 2020-02-24 | 2021-02-10 | 2022-02-09 | 2023-02-14 | NaN | NaN |
| period | 12M | 12M | 12M | 12M | 12M | 12M | 12M | NaN | NaN |
| rev | 19427 | 20776 | 22561 | 26145 | 42518 | 46385 | 46159 | 31996 | 12420 |
| revgrowth | NaN | 6.71% | 8.24% | 14.74% | 48.63% | 8.70% | -0.49% | 14.42% | 17.45% |
| earn | 4457 | 1007 | 4920 | 3439 | -9015 | 6994 | 6327 | 2590 | 5480 |
| earnx | 4457 | 3903 | 4976 | 3439 | -9015 | 6994 | 6327 | 3012 | 5453 |
| margin | 22.94% | 4.85% | 21.81% | 13.15% | -21.20% | 15.08% | 13.71% | 10.05% | 15.04% |
| xmargin | 22.94% | 18.79% | 22.06% | 13.15% | -21.20% | 15.08% | 13.71% | 12.07% | 15.18% |
| earningyld | 5.04% | 1.01% | 5.91% | 3.20% | -6.58% | 5.11% | 4.17% | 2.55% | 4.34% |
| cfop | 3058 | 5275 | 5940 | 8067 | 14052 | 16207 | 13066 | 9381 | 5040 |
| cfinv | 1480 | -66.0 | -874 | -9770 | -10859 | -538 | -1062 | -3098 | 5009 |
| cffin | -2653 | -4077 | -3535 | 7621 | -1151 | -16224 | -16962 | -5283 | 8671 |
| cfopmargin | 15.74% | 25.39% | 26.33% | 30.85% | 33.05% | 34.94% | 28.31% | 27.80% | 6.34% |
| cfinvmargin | 7.62% | -0.32% | -3.87% | -37.37% | -25.54% | -1.16% | -2.30% | -8.99% | 16.14% |
| cffinmargin | -13.66% | -19.62% | -15.67% | 29.15% | -2.71% | -34.98% | -36.75% | -13.46% | 22.28% |
| shares | 1643 | 1616 | 1601 | 1674 | 2208 | 2196 | 2099 | 1862 | 288 |
| fx | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0 |
| price | 53.8 | 61.9 | 52.0 | 64.2 | 62.0 | 62.4 | 72.3 | 61.2 | 6.76 |
| dilution | NaN | -1.68% | -0.91% | 4.48% | 27.68% | -0.58% | -4.51% | 4.08% | 11.92% |
| dividend | 2547 | 2577 | 2613 | 2679 | 4075 | 4396 | 4634 | 3360 | 958 |
| sharebb | NaN | 1585 | 836 | -4261 | -33700 | 791 | 6519 | -4705 | 14610 |
| ltdebtbb | NaN | -1259 | 1329 | -37741 | -4949 | 8731 | 4549 | -4890 | 16767 |
| mgtbb | NaN | -1174 | 1243 | -31702 | -35725 | -2306 | -1260 | -11821 | 17045 |
| divyld | 2.88% | 2.58% | 3.14% | 2.49% | 2.97% | 3.21% | 3.05% | 2.90% | 0.28% |
| sharebbyld | NaN | 1.68% | 0.91% | -4.48% | -27.68% | 0.58% | 4.51% | -4.08% | 11.92% |
| mgtyld | NaN | -1.17% | 1.49% | -29.50% | -26.08% | -1.68% | -0.83% | -9.63% | 14.15% |
Balance Sheet
| EndDate | 2016-12-31 | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | mean | std |
|---|---|---|---|---|---|---|---|---|---|
| sourceDate | 2017-02-21 | 2018-02-13 | 2019-02-25 | 2020-02-24 | 2021-02-10 | 2022-02-09 | 2023-02-14 | NaN | NaN |
| mktcap | 88391 | 100073 | 83219 | 107475 | 136982 | 136896 | 151742 | 114968 | 26802 |
| mktcapgrowth | NaN | 12.41% | -18.44% | 25.58% | 24.26% | -0.06% | 10.30% | 9.01% | 16.47% |
| totAsset | 33707 | 33551 | 34986 | 129944 | 118481 | 109314 | 96820 | 79543 | 43671 |
| assetgrowth | NaN | -0.46% | 4.19% | 1.31 | -9.24% | -8.05% | -12.14% | 17.59% | 55.99% |
| curAsset | 13704 | 14854 | 17160 | 29354 | 30192 | 33262 | 27273 | 23686 | 8157 |
| curAssetPct | 40.66% | 44.27% | 49.05% | 22.59% | 25.48% | 30.43% | 28.17% | 34.38% | 10.20% |
| totLiab | 17530 | 21810 | 20955 | 78346 | 80659 | 73368 | 65759 | 51204 | 29497 |
| totLiabPct | 52.01% | 65.01% | 59.90% | 60.29% | 68.08% | 67.12% | 67.92% | 62.90% | 5.90% |
| curLiab | 8841 | 9563 | 10654 | 18304 | 19080 | 21868 | 21890 | 15743 | 5841 |
| curLiabPct | 26.23% | 28.50% | 30.45% | 14.09% | 16.10% | 20.00% | 22.61% | 22.57% | 6.21% |
| ltDebt | 5716 | 6975 | 5646 | 43387 | 48336 | 39605 | 35056 | 26389 | 19386 |
| ltDebtPct | 16.96% | 20.79% | 16.14% | 33.39% | 40.80% | 36.23% | 36.21% | 28.64% | 10.32% |
| Equity | 16177 | 11741 | 14031 | 51598 | 37822 | 35946 | 31061 | 28339 | 14857 |
| EquityPct | 47.99% | 34.99% | 40.10% | 39.71% | 31.92% | 32.88% | 32.08% | 37.10% | 5.90% |
| PB | 5.46 | 8.52 | 5.93 | 2.08 | 3.62 | 3.81 | 4.89 | 4.90 | 2.05 |
Beta
len=92.0
mean=-1.02%
sd=23.32%
alpha=0.11%
beta=36.36%
r_sq=9.00%
lastdate=2023-03-17
firstdate=2016-05-31
logret1y=-9.32%
Financial Snapshot
CompanyName=Bristol-Myers Squibb Co
ID=1
Name=Ordinary Shares
Ticker=BMY
ISIN=None
RIC=BMY
DisplayRIC=BMY.N
InstrumentPI=263066
QuotePI=1089554
InstrumentPermID=8590937206
QuotePermID=55838320292
Exchange=New York Stock Exchange
ExchangeCode=NYSE
ExchangeCountry=USA
CoStatus=Active
CoType=Equity Issue
LastModified=2023-03-16
LatestAvailableAnnual=2022-12-31
LatestAvailableInterim=2022-12-31
Employees=34300
SharesOut=2.099e+09
TotalFloat=2.097e+09
ReportingCurrency=USD
MostRecentExchange=1.0
Industry=Pharmaceuticals (NEC)
IndustryCode=5620104010
NPRICE=66.5
NHIG=81.4
NLOW=65.3
PDATE=2023-03-17
VOL10DAVG=10.1
EV=169699
MKTCAP=139632
AREV=46159
AEBITD=21943
ANIAC=6327
AEPSXCLXOR=2.95
AREVPS=21.5
ABVPS=15.0
ACSHPS=4.46
ACFSHR=7.75
ADIVSHR=2.16
AGROSMGN=78.2
AROEPCT=18.9
APR2REV=3.03
APEEXCLXOR=22.5
APRICE2BK=4.44
ConsRecom=2.26
TargetPrice=81.2
ProjLTGrowthRate=4.06
ProjPE=8.25
ProjSales=47013
ProjSalesQ=11598
ProjEPS=8.07
ProjEPSQ=2.00
ProjProfit=16949
ProjDPS=2.29
quoteccy=USD
quotefx=100.00%
exchgccy=USD
exchgfx=100.00%
tick=None
exchg=None
Valuation
ticker=BMY
exchg=AMEX
RIC=BMY
CompanyName=Bristol-Myers Squibb Co
ExchangeCode=NYSE
Industry=Pharmaceuticals (NEC)
IndustryCode=5620104010
sector=56 Healthcare
region=us
ccy=USD
fx=100.00%
mktcap_usd=139632
float_usd=139534
ConsensRecom=2.26
earning_yield=3.20%
growth=14.41%
dilution=4.07%
margin=10.05%
searning_yield=-1.23%
sgrowth=-1.48%
smargin=-3.87%
sdilution=14.93%
projearning_yield=11.44%
earning_excl_yield=4.34%
div_ratio=90.82%
bb_ratio=-1.25
sh_payout_ratio=0
PS=3.09
price=66.5
ratio=44.67%
sratio=0
sratiopaid=0
ratioConsens=1.22
turnover=47.17%
cfmargin=13.46%
rdmargin=22.38%
scfmargin=-7.17%
quoteccy=USD
quotefx=100.00%
ratiopaid=24.13%
dt=2023-03-17
assetgrowth=17.60%
dlnfx=0